Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.

Kanwal W, Narjis K, Musani S, Nancy F, Qureshi L, Mudasir M, Naseem R, Tooba F, Yousuf J, Farhan K, Javed H, Eljack MMF

DOI: 10.1186/s12885-025-13749-1
Published: 2025 Mar 1
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-025-13749-1,
  title = {Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.},
  author = {Kanwal W and Narjis K and Musani S and Nancy F and Qureshi L and Mudasir M and Naseem R and Tooba F and Yousuf J and Farhan K and Javed H and Eljack MMF},
  year = {2025},
  journal = {BMC cancer},
  doi = {10.1186/s12885-025-13749-1},
  url = {https://doi.org/10.1186/s12885-025-13749-1}
}

RIS

TY  - JOUR
TI  - Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.
AU  - Kanwal W
AU  - Narjis K
AU  - Musani S
AU  - Nancy F
AU  - Qureshi L
AU  - Mudasir M
AU  - Naseem R
AU  - Tooba F
AU  - Yousuf J
AU  - Farhan K
AU  - Javed H
AU  - Eljack MMF
PY  - 2025
JO  - BMC cancer
DO  - 10.1186/s12885-025-13749-1
UR  - https://doi.org/10.1186/s12885-025-13749-1
ER  -

APA

W, K., K, N., S, M., F, N., L, Q., M, M., R, N., F, T., J, Y., K, F., H, J., & MMF, E. (2025). Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.. BMC cancer. https://doi.org/10.1186/s12885-025-13749-1

Source records

pubmed · retrieved 2026-09-26T10:43:25.951Z